CTLA4 and neoplasm: The results of PET and ex vivo biodistribution studies in immune deficient BALB/c mice grafted with syngeneic mouse tumor model (CT26), which expresses CTLA-4, indicated specific uptake of [64Cu]Cu-DOTA-anti-mouse CTLA-4 mAb when compared to the IgG control mAb [91].